Last updated: February 20, 2024
Sponsor: Nanjing First Hospital, Nanjing Medical University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Rosacea
Treatment
Botulinum Toxin Type A Injection [Botox]
Clinical Study ID
NCT06282679
KY20220701-03
Ages 18-60 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
- Meeting the diagnostic criteria of mild to moderate erythema telangiectasis rosetteacne;
- more than 18 years old;
- to obey the rules of the treatment in the study, and can be followed up for 12 weeks;
- informed consent;
Exclusion
Exclusion Criteria:
- Had received facial cosmetic surgery or botulinum toxin treatment within 6 monthsbefore this treatment;
- due to systemic diseases such as autoimmune diseases or menopause facial flush;
- had allergies botulinum toxin;
- pregnant or breastfeeding;
- other facial skin or oral disease therapy, including research before 4 weeks rose acneaccept other treatment;
- With basic neuromuscular diseases (such as myasthenia gravis, amyotrophic lateralsclerosis, etc.);
- All landowners 4 weeks before the study whether any oral aminoglycoside drugs,benzodiazepines drugs or muscle relaxants; .Was removed during treatment observationdata is not complete, incomplete treatment and patients can't take medication asprescribed.
Study Design
Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Botulinum Toxin Type A Injection [Botox]
Phase:
Study Start date:
April 01, 2022
Estimated Completion Date:
June 28, 2024
Study Description
Connect with a study center
Jie Dai
Nanjing, Jiangsu 210006
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.